Fifty-five @entity1 with adult-onset @entity2338 (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life (QOL). GH and placebo were administered for 9 months each, separated by a 4-month washout period. GH therapy was individually dosed to obtain an @entity442 concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for @entity1 and 1.8 IU/day for @entity1 . Mean @entity442 concentration at baseline was higher in @entity1 than in @entity1 (95+/-33 vs 68+/-41 microg/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9+/-2.9 kg and lean body mass was increased by 1.8+/-2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density @entity165 levels decreased. Absolute maximal @entity26 uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

Low-dose GH improves exercise capacity in adults with XXXX : effects of a 22-month placebo-controlled, crossover trial.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity2338 :: ('MESH:D004393', 'Disease') :: ['GH deficiency'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity442 :: ('3479', 'Gene') :: ['IGF-I'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity2338 :: (MESH:D004393,Disease) :: ['GH deficiency']
